Clinical Trial Detail

NCT ID NCT02559687
Title Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

esophagus squamous cell carcinoma

esophagus adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.